Abstract The RAS–RAF–MEK–ERK signaling cascade is among the most frequently mutated
pathways in human cancer. Approximately 50% of melanoma patients possess a druggable …

The identification of mutationally activated BRAF in many cancers altered our conception of
the part played by the RAF family of protein kinases in oncogenesis. In this Review, we …

Papillary thyroid carcinoma (PTC) is the most common type of thyroid cancer. Here, we
describe the genomic landscape of 496 PTCs. We observed a low frequency of somatic …

Human cancer genomes harbour a variety of alterations leading to the deregulation of key
pathways in tumour cells. The genomic characterization of tumours has uncovered …

Histiocytic neoplasms are clonal, hematopoietic disorders characterized by an accumulation
of abnormal, monocyte-derived dendritic cells or macrophages in Langerhans cell …

Structural gene rearrangements resulting in gene fusions are frequent events in solid
tumours. The identification of certain activating fusions can aid in the diagnosis and effective …

Colorectal carcinoma represents a heterogeneous entity, with only a fraction of the tumours
responding to available therapies, requiring a better molecular understanding of the disease …

Abstract Knowledge of key drivers and therapeutic targets in mucosal melanoma is limited
due to the paucity of comprehensive mutation data on this rare tumor type. To better …

Although the BRAF V600E base substitution is an approved target for the BRAF inhibitors in
melanoma, BRAF gene fusions have not been investigated as anticancer drug targets. In our …

Liquid–liquid phase separation (LLPS) is emerging as a mechanism of spatiotemporal
regulation that could answer long-standing questions about how order is achieved in …